BioWorld. Link to homepage.

Clarivate
  • BioWorld
  • BioWorld MedTech
  • BioWorld Asia
  • BioWorld Science
  • Data Snapshots
    • BioWorld
    • BioWorld MedTech
    • Infographics: Dynamic digital data analysis
    • Index insights
    • NME Digest
  • Special reports
    • Infographics: Dynamic digital data analysis
    • Trump administration impacts
    • Under threat: mRNA vaccine research
    • BioWorld at 35
    • Biopharma M&A scorecard
    • BioWorld 2024 review
    • BioWorld MedTech 2024 review
    • BioWorld Science 2024 review
    • Women's health
    • China's GLP-1 landscape
    • PFA re-energizes afib market
    • China CAR T
    • Alzheimer's disease
    • Coronavirus
    • More reports can be found here

BioWorld. Link to homepage.

  • Sign In
  • Sign Out
  • My Account
Subscribe
BioWorld - Tuesday, December 9, 2025
Home » Newsletters » BioWorld Science

BioWorld Science

Feb. 16, 2018

View Archived Issues

Vertex announces positive results for VX-150 in relief of acute pain

Read More

Novel transgelin-2 agonist reduces asthmatic pulmonary resistance in mice

Read More

Overall survival improved with OMS-721 in thrombotic microangiopathy trial

Read More

siCAG/CUG shown as promising new gene therapy for cancer

Read More

Somatic and neurological effects seen with AGT-181 in patients with MPS type I

Read More

First-in-human study of ARO-HBV cleared; ARO-AAT granted U.S. orphan status

Read More

FDA grants fast track designation to Allecra's AAI-101 in fixed-dose combination with cefepime

Read More

TRDN user survey - We want your opinion

Read More

FDA approves Makena subcutaneous atuoinjector

Read More

Shire reviews key development highlights of fourth quarter 2017

Read More

OR51T1 predicts hormone therapy efficacy in men with mHNPC

Read More

Intralytix cleared to begin phase I/IIa trials of bacteriophage preparation

Read More

Nodthera patents new NLRP3 inflammasome inhibitors

Read More

Agios Pharmaceuticals submits NDA for ivosidenib for acute myeloid leukemia

Read More

Results from phase III trial of avelumab in advanced NSCLC

Read More

Accro Bioscience divulges necrosis inhibitors

Read More

Bristol-Myers Squibb Co. presents new TGFBR inhibitors

Read More

CARB-X funds Curza's development of Gram-negative antibiotic program

Read More

Pfizer patents novel C5a1 receptor antagonists

Read More

Sanofi exercises option to license additional multi-specific Nanobodies from Ablynx

Read More

New isochroman derivatives presented by Sunovion Pharmaceuticals

Read More

FDA accepts Shire's sBLA for the use of Cinryze in children

Read More

Miglustat stabilizes ATB-200 in the circulation of Pompe disease patients

Read More

Debiopharm Group acquires minority stake in ABAC Therapeutics

Read More

Xeris completes two phase III studies of its ready-to-use glucagon rescue pen

Read More

Otsuka Pharmaceutical updates pipeline progress of fourth quarter 2017

Read More

Daiichi Sankyo seeks Japanese approval of mirogabalin for peripheral neuropathic pain

Read More

Genethon begins trial of gene therapy for Crigler-Najjar Syndrome

Read More

Miticure approved in Japan for pediatric patients with house dust mite-induced allergic rhinitis

Read More

Popular Stories

  • Today's news in brief

    BioWorld
    BioWorld briefs for Dec. 8, 2025.
  • Today's news in brief

    BioWorld MedTech
    BioWorld MedTech briefs for Dec. 8, 2025.
  • Mesothelin is biomarker, potential target in arthritic bone damage

    BioWorld Science
    In a recent study published in Cell Reports Medicine, researchers from the Institute of Chinese Materia Medica of the China Academy of Chinese Medical Sciences...
  • 3D rendering of prion structure

    Epigenetic technology could eliminate misfolded prion proteins

    BioWorld Science
    The number of deaths caused by prion diseases reaches about 30,000 annually. Only 5 months pass from the diagnosis of seemingly healthy patients to the fatal...
  • Novo Nordisk semaglutide pill

    CTAD 2025: Diagnosing semaglutide’s failure in Alzheimer’s trials

    BioWorld
    A little over a week after announcing that the Evoke and Evoke+ studies failed to show that oral semaglutide could slow cognition decline in patients with...
  • BioWorld
    • Today's news
    • Analysis and data insight
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Newco news
    • Opinion
    • Regulatory
    • Science
  • BioWorld MedTech
    • Today's news
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Newco news
    • Opinion
    • Regulatory
    • Science
  • BioWorld Asia
    • Today's news
    • Analysis and data insight
    • Australia
    • China
    • Clinical
    • Deals and M&A
    • Financings
    • Newco news
    • Regulatory
    • Science
  • BioWorld Science
    • Today's news
    • Biomarkers
    • Cancer
    • Conferences
    • Endocrine/Metabolic
    • Immune
    • Infection
    • Neurology/Psychiatric
    • NME Digest
    • Patents
  • More
    • About
    • Advertise with BioWorld
    • Archives
    • Article reprints and permissions
    • Contact us
    • Cookie policy
    • Copyright notice
    • Data methodology
    • Infographics: Dynamic digital data analysis
    • Index insights
    • Podcasts
    • Privacy policy
    • Share your news with BioWorld
    • Staff
    • Terms of use
    • Topic alerts
Follow Us

Copyright ©2025. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing